Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Qigui Yishen Prescription** is an investigational traditional Chinese multi-herb decoction for kidney disease. It has been studied clinically in chronic kidney disease and in platinum anticancer therapy-associated acute and chronic kidney injury. In a unilateral ureteral obstruction animal model, the decoction reduced renal interstitial fibrosis and was associated with lower renal plasminogen activator inhibitor-1, transforming growth factor beta 1, and collagen I expression and higher thrombomodulin expression. These findings are preclinical and do not establish a defined direct molecular target or clinical efficacy. ([chictr.org.cn](https://www.chictr.org.cn/showproj.aspx?proj=134648))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qigui Yishen Prescription.